symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ELEV,0.649,0.368157,174976,27505918,0,0.51-5.89,-0.0241,"Elevation Oncology, Inc.",USD,0001783032,US28623U1016,28623U101,NASDAQ Global Select,NASDAQ,Biotechnology,https://elevationoncology.com,"Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.",Mr. Joseph J. Ferra Jr.,Healthcare,US,33,716 371 1125,888 Seventh Avenue,New York,NY,10106,,0,https://financialmodelingprep.com/image-stock/ELEV.png,2021-06-25,False,False,True,False,False
